Hybrid closed-loop insulin delivery systems (HCLs) are an emerging technology for the management of type 1 diabetes. HCLs combine an insulin pump with a continuous glucose monitor (CGM) and a computer program. Together, these use information from the CGM to automatically determine insulin needs throughout the day and keep the user within a pre-determined blood glucose range. They are called hybrid systems because users must still manually account for insulin needs before and after meals.
It has been noted that, across Canada, technologies to manage type 1 diabetes are rapidly evolving. There is a need to understand the place in care, if any, HCLs may have compared with existing technologies.
CADTH undertook an Optimal Use project to develop recommendations by assessing the clinical effectiveness and safety, the budget impact, perspectives and experiences, and ethical issues related to the use of hybrid closed loop systems by people living with type 1 diabetes.